Abstract:Diabetic kidney disease (DKD) is one of the major microvascular complications of diabetes and an important cause of end-stage renal disease. Previous studies have shown that the damage to podocyte autophagy is related to the pathogenesis of DKD, and this damage is closely mediated by the Janus kinase (JAK)/signal transductors and the transcription (STAT) signaling pathway. Here, the underlying molecular mechanism of the JAK/STAT signaling pathway regulating podocyte autophagy was investigated. In the present study, compared to controls, DKD mice showed glomerular hypertrophy, increased kidney weight/weight ratio, and increased urinary protein levels, as well as decreased desmin and synaptopodin expression. Meanwhile, levels of triglyceride, total cholesterol, reduced glutathione, and malondialdehyde were also increased in the serum of DKD mice. Further, a lower number of autophagosomes, reduced expression of MAP1LC3 (LC3) in glomeruli, and increased expression of JAK/STAT pathway-related proteins, namely JAK1, JAK2, STAT1, STAT3, STAT5, and STAT6, were observed in DKD mice. In the in vitro experiments, we observed impaired autophagy, enhanced apoptosis, and activated JAK/STAT pathway in podocytes under high glucose conditions. Studies using ruxolitinib inhibitors have showed that suppression of the JAK/STAT pathway in podocytes subjected to high glucose could increase autophagic flux and autophagy-related protein expression. Taken together, the present study demonstrates that high glucose inhibits autophagy by activating the JAK/STAT pathway in mice and podocytes, thereby preventing the efficient removal of damaged proteins and organelles from the body to prevent apoptosis, and ultimately aggravating the progression of podocyte injury and DKD.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the specific molecular mechanism by which hyperglycemia inhibits podocyte autophagy through activating the JAK/STAT signaling pathway, thereby aggravating the progression of diabetic kidney disease (DKD). Specifically, the researchers focused on: 1. **The relationship between the JAK/STAT signaling pathway and DKD**: The researchers found that in diabetic kidney disease model mice, the expression of key proteins in the JAK/STAT signaling pathway (such as JAK1, JAK2, STAT1, STAT3, STAT5, and STAT6) increased significantly, indicating that the JAK/STAT signaling pathway is activated during the development of diabetic kidney disease. 2. **The role of autophagy in DKD**: The researchers observed that the number of autophagosomes in podocytes of diabetic kidney disease model mice decreased, and the expression of LC3 protein also decreased, indicating that autophagy is inhibited in diabetic kidney disease. Meanwhile, podocytes cultured under high - glucose conditions also showed a decrease in autophagic activity, further confirming the inhibitory effect of hyperglycemia on autophagy. 3. **The influence of the JAK/STAT signaling pathway on autophagy**: To verify whether the JAK/STAT signaling pathway affects the progression of diabetic kidney disease by inhibiting autophagy, the researchers used the JAK inhibitor ruxolitinib. The results showed that ruxolitinib can inhibit the activation of the JAK/STAT signaling pathway in podocytes under high - glucose conditions, restore the expression of autophagy - related proteins, and increase the autophagic flux. In summary, the main purpose of this study is to reveal the molecular mechanism by which hyperglycemia causes podocyte damage and the progression of diabetic kidney disease by inhibiting podocyte autophagy through activating the JAK/STAT signaling pathway, and to explore the possibility of improving diabetic kidney disease by inhibiting the JAK/STAT signaling pathway.

JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes